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It is a very interesting study and well written paper. However, I have some major issues with the study results , and some minor with the analyses and discussion, that should be addressed by the authors:
Two major issues that I have with the study design/results are:
1. Why did all the patients had ASA stopped before the CABG surgery? (it is stated the ASA was stopped at least 5 days before surgery). According to ACC/AHA guidelines (even in 2011 when the study started) -ASA should not be discontinued before surgery. 2. It seems like in the study there were very small number of 1-year MACCE (any nonfatal MI, stroke, repeated revascularization, and death from any cause): 56 out of 1655, which gives 3.3%. And just two MIs during 1-year follow-up after CABG (0.1%) ? Could you please comment on it?
Minor issue: The latter paper discusses also the long term production of TXB2 in one year follow up after AMI. Something that may be useful for discussion in current article. 11-dehydro-TXB2 was elevated during acute event and substantially decreased at both 1-month and 1-year follow-up.
These papers should be mentioned in the discussion section. 
GENERAL COMMENTS
In the present manuscript, Liu et al. aimed to investigate whether perioperative urinary 11-dehydro-TXB2 (TX-M) levels are associated with major adverse cardiac and cerebrovascular events (MACCE) after coronary artery bypass graft (CABG) surgery, in a nested casecontrol study They found that perioperative urinary TX-M level is associated with one-year adverse events after CABG, which raises the potential possibility that high levels of perioperative TX-M identify patients with high risk of post-CABG adverse event.
This is an interesting study. However, I raised several points to be addressed by the authors.
Major points
They used the AspirinWorks by Corgenix; however it is quite important to know the hours of urine collections for the assessment of 11-dehydro-TXB2 levels. For my experience the collection should be of at least 6-8 h otherwise the values are quite variable.
Moreover, the urine samples should be extracted to avoid the occurrence of interferences. The values are quite high. They should report the concentrations detected in healthy subjects using this assay to verify if the values were comparable to those detected with other immunoassays.
A possible determinant of the one-year adverse events after CABG associated with high levels of perioperative TX-M may reflect platelet activation and possibly inadequate response to aspirin treatment. Thus, it is an important limitation that they did not assess TX-M values under aspirin treatment.
The hypothesis that enhanced TX-M levels are COX-2 derived is not easy to demonstrate because TX-M is mainly of platelet origin also in cardiovascular disease. This could be confirmed by assessing the impact of low-dose aspirin.
To give a mechanistic interpretation of their findings, it should be useful to assess other eicosanoids in urine and also F2-isoprostanes, indexes of oxidative stress, which may activate the TP receptors.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Wojciech Szczeklik Two major issues that I have with the study design/results are: 1. Why did all the patients had ASA stopped before the CABG surgery? (it is stated the ASA was stopped at least 5 days before surgery). According to ACC/AHA guidelines (even in 2011 when the study started) -ASA should not be discontinued before surgery. Answer: Although in 2011, it is recommended in ACC/AHA guidelines that ASA should not be discontinued before CABG, controversial evidence still exists for benefits vs. risks of preoperative aspirin use in CABG patients1 and some studies also have demonstrated increased risk of perioperative bleeding and surgical re-exploration with pre-CABG aspirin use2. On the other hand, it would take some time, which may not be short, to put the recommendation of ACC/AHA guidelines into effect in China thoroughly. In 2011, the ASA administration in our hospital is not that strict. Some wards in our hospital comply with the ACC/AHA guidelines well and ASA was not discontinued before cardiac surgery; while, in some other wards, it is still a common practice to withhold aspirin 5 days before CABG for fear of post-operative bleeding complications for patients with stable angina undergoing CABG based on prior guidelines3. In this study, all the patients had ASA stopped before the CABG surgery, so for this point all patients are comparable and this may not bring in new bias or have great influence on the endpoint of this study. And in the future, the conclusion of this study will be further confirmed in patients, who do not stop ASA before CABG. The latter paper discusses also the long term production of TXB2 in one year follow up after AMI. Something that may be useful for discussion in current article. 11-dehydro-TXB2 was elevated during acute event and substantially decreased at both 1-month and 1-year follow-up. These papers should be mentioned in the discussion section. Answer: We have added these three articles in the discussion section in our manuscript according to your comments.
2. Did the patients had cardiac troponins measured after surgery? If so -did the levels of troponins correlated with TXA-M level. Answer: Linear regression models were used to clarify the relationships between TXA-M (pre-CABG, post-CABG 6h, post-CABG 24h) and cTnI or CK-MB and we found that there is no significant correlation between TXA-M and cTnI or TXA-M and CK-MB.
3. Did the results of TXA-M correlated with EF from echocardiographic examination? Answer: Linear regression models were used to clarify the relationships between TXA-M (pre-CABG, post-CABG 6h, post-CABG 24h) and EF and we found that there is no significant correlation between these two variables.
4. It seems there is a mistake in the Results section -(line 163), where it stays that 84 patients with MACCE group received rosuvastatin (there were only 56 events). Answer: It should be 84 patients in non-MACCE. We have corrected it in the revised manuscript.
5. Please add in footnotes of table 4 the variables used in the COX regression model Answer: We have added all variables used in COX regression model in the footnotes, which you can see in our revised manuscript.
Reviewer: 2 Reviewer Name: Paola Patrignani Major points 1. They used the Aspirin Works by Corgenix; however it is quite important to know the hours of urine collections for the assessment of 11-dehydro-TXB2 levels. For my experience the collection should be of at least 6-8 h otherwise the values are quite variable. Moreover, the urine samples should be extracted to avoid the occurrence of interferences. The values are quite high. They should report the concentrations detected in healthy subjects using this assay to verify if the values were comparable to those detected with other immunoassays. Answer: According to the design of this study and the STICS trial, all subjects enrolled in our study are CAD patients, so we were not able to collect the urine sample from healthy subjects. As for the assessment of TXM, we strictly follow the protocol of manufacturer. After collection, all urine sample were kept in -80 degree centigrade within 1 hour and thawed on ice before assessment. Furthermore, as for the value of TXM, we found that using the same kit, the urine TXM level in some other studies was also very high( J Thromb Haemost 2012;10:1949-51).
2. A possible determinant of the one-year adverse events after CABG associated with high levels of perioperative TX-M may reflect platelet activation and possibly inadequate response to aspirin treatment. Thus, it is an important limitation that they did not assess TX-M values under aspirin treatment. Answer: In our study, the urine samples were obtained at 3 time points (1hour before CABG, 6 hours and 24hours after CABG), and in this period ASA treatment is the same in all enrolled patients. In our hospital, the medication of ASA stopped at least 5 days before CABG and postoperatively, starting within the first 24 hours post-operation (100mg). So in our study, the generation of TXB2 and the level of urine TXM could not reflect the effect of ASA on the activation of platelet, however it could reflect the inflammation status and some other cardiac surgery related stress, which may also have influence on the 1-year outcome of CAD patients underwent CABG.
3. The hypothesis that enhanced TX-M levels are COX-2 derived is not easy to demonstrate because TX-M is mainly of platelet origin also in cardiovascular disease. This could be confirmed by assessing the impact of low-dose aspirin. Answer: Restricted by the enrollment of patients, who stopped ASA 5 days before the surgery, we were not able to assess the impact of low-dose aspirin in our study. The generation of TXB2 and the level of urine TXM in our study could not reflect the effect of ASA on the activation of platelet, while, to some extent, it could reflect the COX-2 activation under systemic inflammation status and some other cardiac surgery related stress. So in this study, we inclined to emphasize the influence of inflammatory stimuli on the generation of TXB2 and the increase of urine TXM, not the aspirin resistant.
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